Skip to main content
One Health logoLink to One Health
. 2024 Aug 5;19:100871. doi: 10.1016/j.onehlt.2024.100871

One Health policy for combatting African trypanocide resistance

Keneth Iceland Kasozi a,b,, Ewan Thomas MacLeod a, Susan Christina Welburn a,c,d,e,
PMCID: PMC11367463  PMID: 39224765

Abstract

The rise of African trypanocide resistance (ATr) is influenced by various factors such as evolutionary changes in the pathogen, the presence of resistance genes in the population, poor policy decisions, limited private-public partnerships to engage local communities, and insufficient funding for the development of new drugs over the past sixty years. These challenges have been exacerbated by the inadequate implementation of drug liberalization policies in the mid 20th century, leading to poor pharmacovigilance practices for veterinary drugs in low and middle income countries (LMICs). One health (OH), a disease management framework, provides practical solutions for addressing ATr, drawing on its success in managing previous epidemics like avian influenza in 2004 and the recent COVID-19 pandemic, where institutional collaborations were rapidly established. To combat ATr, OH initiatives involving both international and local partners at the policy and grassroots levels are crucial to generate community interest. The importance of political commitment, media involvement, and nongovernmental organizations cannot be overstated, as they are essential for resource mobilization and long-term sustainability in LMICs.

Keywords: Neglected tropical diseases, One Health, COVID-19, Trypanosomiasis, Developing countries, Global health, Funding, Infectious diseases

1. Introduction

There is increasing scientific evidence for the evolution of antimicrobial drug resistance (AMR) to the drugs available to treat human African trypanosomes (HAT) and animal African trypanosomiasis (AAT) [1,2]. In most rural communities, inappropriate use of trypanocides is considered to confer selection pressure for resistance genes to develop in trypanosome populations [3]. The emergence of drug resistance phenotypes has complicated both control AAT and impeded progress towards the elimination of HAT as a public health problem by 2030 [4,5]. Drug resistant trypanosomes have been found in humans [6], livestock [7] and the tsetse fly insect vector [8] and this is a key concern due to weak regulatory policies contributing to the growing antimicrobial resistance (AMR) in endemic countries. Given the emergence of drug resistance and lack of new trypanocides in development for AAT, the use of chemotherapy alone as a primary method to control AAT in sub–Saharan Africa is no longer a sustainable approach [9].

The fear of influenza pandemics was instrumental in galvanizing international attention and collaborative efforts which led to the birth of one-health (OH). The global anxiety surrounding the highly pathogenic avian influenza (HPAI) subtype H5N1, commonly known as bird flu in 2004 was driven by its high mortality rate in poultry and the potential for the virus to mutate and spread to humans, causing a severe and widespread outbreak [10]. This provided an opportunity to unify the Food and Agriculture Organization (FAO), World Organization for Animal Health (WOAH), World Health Organization (WHO) and the World Bank and develop comprehensive strategies to address emerging zoonotic diseases [11,12]. By fostering collaborations, these agencies pool their expertise and resources to develop more effective strategies to address zoonotic diseases. Interdisciplinary collaborations bring together experts from various fields, including veterinarians, epidemiologists, environmental scientists, public health professionals, and economists. This creates a complex web while developing comprehensive solutions. Furthermore, international, and national authorities having equal partnership demonstrates a need for a strong leadership platform. The threat of HPAI H5N1 did recede (A. L. [13]), however, COVID-19 demonstrated the importance of having a strong operational OH policy in place [14]. Furthermore, OH in rabies control has been associated with a drop in the number of cases and helped veterinarians gain more confidence in handling cases, reduced production costs and increased sharing of information between veterinarians and medical sectors [15], despite the limited rabies surveillance systems which are scarce in Africa [16]. In Latin America, the commitment and engagement of the health sector have been pivotal in integrating rabies control into broader national rabies control programs. This integration has significantly contributed to the successful implementation of OH principles in the region [17]. COVID-19 exposed the dysconnectivity between governmental promotion of OH and the reality outside of governmental agencies [18,19]. OH creates a platform for leadership and knowledge sharing, as exemplified by the Canadian OH platform which has members from the political sciences, sociology, law, economics, anthropology, veterinary, human health, public health, environmental sciences, epidemiology and implantation research [20]. In line with the WHO post COVID-19 preparedness plan for the next pandemic (Tedros [21]), OH offers a feasible platform to address the growing African trypanocide resistance challenge on the African continent. In essence, by addressing diseases in animal populations, we not only protect the health and welfare of animals but also contribute to the broader goals of ecosystem health, biodiversity conservation, and sustainable resource management. This holistic approach is crucial for maintaining healthy and resilient ecosystems in the face of global challenges.

1.1. Liberalization of the African trypanocide industry

Demands to open the African market/industry for drug manufacture and supply have led to the establishment of local manufacturing pharmaceutical companies with linkages to multinational European counterparts. Severe economic pressures and declining manufacturing in the late 1970s were associated with the birth of the liberalization policy which included the pharmaceutical industry in several African countries [22]. For effective prevention of AMR development, national regulatory frameworks are required, ideally established by thorough intergovernmental collaborations on OH. These help develop and promote good manufacturing practice (GMP) regulations regionally and enable harmonized monitoring strategies [23]; GMP remains a significant challenge in most low and middle income countries (LIMICs) and the requirement for more active collaboration in drug monitoring and guidance in both human and animal health ministries is long overdue. The World Trade Organization (WTO), WHO, and WOAH are all committed to collaborate more closely to create better infection control strategies [24], but too often communication channels operating at the ministerial level are not translated to grassroot administrative units, making it challenging to implement OH messaging and good practice in these communities.

To address HAT resistance (HATr), collaborative international partners have supported biomedical research into novel therapies such as nifurtimox/eflornithine combinations. Drugs have been repurposed and clinical trials are in advanced stages. In contrast, resources for new drug options for AAT resistance (AATr) are lacking, arising from disproportionate allocation of funding in the WHO/WOAH related biomedical and clinical research [25]. This situation has been worsened further during the COVID-19 pandemic where disproportionate funding has seen increased poverty and marginalization for the control of NTDs in LMICs [26]. Ignoring investment in new drugs and appropriate existing drug use in livestock poses a significant risk to human and animal health, and this is very important in LMICs where veterinary policy is weak (A. L. [27]). The WHO 2021–2030 road map has been updated for the elimination of HAT and AAT as a public health problem [28] which is an update from the previous target were gHAT was a target for transmission alone [4]. This implied WHO prioritized (gambiense) gHAT over (rhodesiense) rHAT (see [29] where new drugs for gHAT are elaborated) and with these new developments, it is apparent Trypanosoma brucei species are now a priority. Attempting to control a zoonotic infection without long-term management of infection in reservoir species is unlikely to be successful. Chronic failures to address AATr also contribute to human spillover infections (HATr) [3]. AATr control is complicated by the weak veterinary policies (poor surveillance, diagnostics and political commitment) in endemic communities [30,31], where net migration (re-stocking and livestock trade) contributes to the re-introduction of infections in human populations (A. L. [27,32]). There was already a funding crisis for tackling neglected tropical diseases (NTDs) [33,34,35], exacerbated by the impacts of COVID-19 and the difficult decisions that needed to be made in the allocation of budgets. Given that some NTDs are widening their range as a result of climate change, travel and trade [36], and considering lessons learned from the COVID-19 pandemic [37], a lack of investment will stifle the WHO/FAO trypanosomiasis elimination target. Taking a more holistic OH approach to infection control can reap significant benefits (A. [38]). For example, OH in East Africa (Uganda) in the control of emerging and re-emerging zoonotic infections i.e., Ebola, Marburg, plague, avian influenza, Rift valley fever, anthrax and yellow fever [39] as well as NTDs, especially on HAT [40] and the strengthening of national laboratories to detect zoonotic infections [41] do provide evidence for the benefits of multidisciplinary-sectoral collaborations. A comprehensive list of successful stories for the control of NTDs through an integration of OH [42] generates momentum for the adoption of OH for the management of ATr in the post pandemic age.

1.2. African trypanocide therapeutics in the COVID-19 age

The Stamp Out Sleeping Sickness (SOS) campaign [43], in Uganda whereby insecticides combined with trypanocides administered in cattle contributed to the reduction of the HAT burden is a classical example were OH has been successful. SOS involved multidisciplinary international collaborative initiative for the control of an NTD in Eastern Africa. Despite challenges associated with the implementation of OH as exemplified through the SOS project under the Coordinating Office for Control of Trypanosomiasis in Uganda (COCTU) such as leadership, ownership, and limited long-term financial support which demonstrated the importance of financial resource allocation to resolve conflicts (A. L. [44]), the COCTU secretariat did receive political endorsement and local support thus making COCTU one of the most successful global OH bodies now being reabsorbed into the Ministry of Health (Uganda) in the post-pandemic era. Another successful case study where OH has been successful involved the rabies campaign in developing countries. In Tanzania during the rabies elimination project funded under the Bill and Melinda Gates Foundation, engagement with several key ministries and the Prime Minister's Office helped to generate momentum for project ownership despite infrastructure challenges due to cold chain for vaccine handling, and road access (A. L. [44]). This provides evidence that OH remains relevant today to address AMR in Neglected Tropical Diseases (NTDs) including challenges of counterfeits that are proliferative in most developing countries.

Inadequate, excessive or substandard antimicrobial drugs contribute to treatment failures, allowing infections to persist and potentially become resistant to available treatments [45]. This situation poses a grave threat to public health, especially in regions where access to quality healthcare and effective medications is already limited [46]. However, across rural communities in sub-Saharan Africa, farmers continue to buy substandard and unregulated trypanocides, for use in their animals, many not licenced in the market into which they are being sold [47] simply because they are cheap, and do not observe safe practice withdrawal periods prior to selling their animal given there is no monitoring in place [48]. From the community perspective, it is inevitable that a smallholder farmer in the absence of professional advice will opt for cheap drugs regardless of quality, but farmer-based treatments characterized by poor dosing, and failure to observe withdrawal periods do raise major public health risks as well as major animal welfare concerns. Concerns as to drug administration by farmers are not limited to trypanocides, and in countries with poor veterinary and human drug regulatory policies, as is common in the global south, lax regulations, infrastructure challenges, and a chronic lack of legal oversight create an environment where AMR can develop, unimpeded. Adoption of a holistic OH approach to combat AMR provides real opportunities for national governments with these infrastructure challenges to maximize the available human resources [49].

The interconnectedness of health as demonstrated by the COVID-19 pandemic and its consequences justifies the social and economic benefits of amalgamating professionals to work under one administrative framework. Unfortunately, while informal memorandums of collaborations between institutions have been written in line with WHO recommendations [50], the adoption of OH has rarely been mainstreamed into Government policy. A multitude of resources have been made available by the WHO to support and guide nations for the institutionalization of OH. Furthermore, WHO has encouraged LMICs to develop collaborative initiatives in preparation for the next pandemic. Most high-income countries (HICs) e.g., USA and UK have developed their response plans as was observed during the early phases of the pandemic [51,52], however, LMICs are at risk of being left behind. Individualism among nations works contrary to the United Nations (UN) Collective Action Plan, however, the political atmosphere in UN member states is responsible for these divergent policy decisions which work against efforts to promote planetary health for the control of epidemics.

The success of the COVID-19 response was, in part, due to strong political leadership and coordinated efforts at various levels of government and international bodies. This was especially important to counteract strange conspiracy theories and denialism (see [53] in the UK, Ireland, Spain, USA and Mexico) thus helping bring diverse perspectives from politics, funders, healthcare and policymaking under one framework [54]. For AMR and NTDs, similar political commitment is crucial. Governments need to prioritize these issues, allocate resources, and support international collaborations. The media played a pivotal role in framing COVID-19 as a pressing global crisis, which drove public engagement and compliance with health measures [55]. To address AMR and NTDs, it is essential to harness media and communication strategies to raise awareness, educate the public, and advocate for urgent action. The pandemic showed the importance of global cooperation. For diseases affecting LMICs, creating and maintaining strong international partnerships among governments, non-governmental organizations, and private sectors can enhance resource mobilization, research, and intervention efforts.

The private sector played a role in developing COVID-19 vaccines and treatments [56], its involvement is critical in the fight against ATr. Engaging pharmaceutical companies, biotech firms, and other private entities can drive innovation and ensure the availability of effective treatments and diagnostics. The Bill and Melinda Gates Foundation through GALVmed approved over USD 19 million for phase 3 trials for new drugs against AAT [57], and more recently collaborations between GALVmed, the UK Government Foreign Commonwealth and Development Office, Boehringer Ingelheim and GALVmed have made a concerted effort to combat ATr [58]. Unfortunately, reciprocal collaborations at the grassroot movements involving LMIC institutions and the government remain scarce. This implies media mobilization to advocate for ATr control at the community level, though crucial remains elusive. Empowering local organizations and communities to participate in and lead health initiatives can improve the effectiveness and sustainability of ATr interventions.

2. Conclusion

Although the WHO, WOAH, WTO, FAO work together, oversight of OH activities remains idealistic especially at the national level. Individualism, protectionism, duplication of research, and corruption as well as a lack of a streamlined leadership framework are major barriers to the realization of the OH strategy for infection control. To improve institutional preparedness in developing countries in anticipation of the perfect pathogen (Pathogen X = infectious like COVID-19, and virulent like Ebola), WHO has promoted OH to reduce spillover events. Without clear national and regional policies on OH, this objective will remain elusory in both HICs and LMICs. A coordinated approach that integrates political will, media engagement, global collaboration, private sector involvement, and grassroots mobilization is essential for addressing ATr effectively. By learning from the COVID-19 response, stakeholders can work together to create a powerful, united front against African trypanosomiasis in LMICs.

Author disclaimer

The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Ethical approval statement

Not applicable.

Funding source

This research was supported by the National Institute for Health Research (16/136/33) using United Kingdom aid from the United Kingdom Government (SCW). This work was also supported by Zhejiang University Research Fund (SCW) and funded by the Commonwealth Scholarship Commission (UGSC–2021–447) in the United Kingdom and the Small Grants Programme of the Royal Society of Tropical Medicine and Hygiene (2021) in partnership with the National Institute for Health Research (NIHR) (KIK).

CRediT authorship contribution statement

Keneth Iceland Kasozi: Writing – review & editing, Writing – original draft, Visualization, Validation, Software, Resources, Methodology, Investigation, Funding acquisition, Conceptualization. Ewan Thomas MacLeod: Writing – review & editing, Validation, Supervision, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation. Susan Christina Welburn: Writing – review & editing, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization.

Declaration of competing interest

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Contributor Information

Keneth Iceland Kasozi, Email: Keneth.kasozi@ed.ac.uk.

Susan Christina Welburn, Email: sue.welburn@ed.ac.uk.

Data availability

No data was used for the research described in the article.

References

  • 1.De Koning P.H. The drugs of sleeping sickness: their mechanisms of action and resistance, and a brief history. Tropi. Med. Infect. Disease. 2020;5(1):14. doi: 10.3390/tropicalmed5010014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Richards S., Morrison L.J., Torr S.J., Barrett M.P., Manangwa O., Mramba F., Auty H. Pharma to farmer: field challenges of optimizing trypanocide use in African animal trypanosomiasis. Trends Parasitol. 2021;37(9):831–843. doi: 10.1016/j.pt.2021.04.007. [DOI] [PubMed] [Google Scholar]
  • 3.Barrett M.P. Veterinary link to drug resistance in human African trypanosomiasis? Lancet. 2001;358(9282):603–604. doi: 10.1016/S0140-6736(01)05817-2. [DOI] [PubMed] [Google Scholar]
  • 4.Franco J.R., Cecchi G., Paone M., Diarra A., Grout L., Kadima Ebeja A.…Argaw D. The elimination of human African trypanosomiasis: achievements in relation to WHO road map targets for 2020. PLoS Negl. Trop. Dis. 2022;16(1) doi: 10.1371/journal.pntd.0010047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.WHO Benin, Uganda and Rwanda Eliminate Human African Trypanosomiasis as a Public Health Problem. 2022. https://www.who.int/news/item/24-05-2022-benin--uganda-and-rwanda-eliminate-human-african-trypanosomiasis-as-a-public-health-problem Retrieved July 27, 2023, from.
  • 6.Baker N., Glover L., Munday J.C., Andres D.A., Barrett M.P., de Koning H.P., Horn D. Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes. Proc. Natl. Acad. Sci. USA. 2012;109(27):10996–11001. doi: 10.1073/pnas.1202885109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Kulohoma B.W., Wamwenje S.A.O., Wangwe I.I., Masila N., Mirieri C.K., Wambua L. Prevalence of trypanosomes associated with drug resistance in Shimba Hills, Kwale County, Kenya. BMC Res. Note. 2020;13(1):234. doi: 10.1186/s13104-020-05077-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Simo G., Magang E.M.K., Mewamba E.M., Farikou O., Kamga R.M.N., Tume C.…Ravel S. Molecular identification of diminazene aceturate resistant trypanosomes in tsetse flies from Yoko in the Centre region of Cameroon and its epidemiological implications. Parasit. Epidemiol. Control. 2020;9 doi: 10.1016/j.parepi.2020.e00135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Welburn S.C., Maudlin I., Simarro P.P. Controlling sleeping sickness - a review. Parasitology. 2009;136(14):1943–1949. doi: 10.1017/S0031182009006416. [DOI] [PubMed] [Google Scholar]
  • 10.Gibbs E.P.J. The evolution of one health: a decade of progress and challenges for the future. Vet. Rec. 2014;174(4):85–91. doi: 10.1136/vr.g143. [DOI] [PubMed] [Google Scholar]
  • 11.Laing G. A year of one health and neglected tropical diseases. Int. Health. 2023;15(5):477–479. doi: 10.1093/inthealth/ihad043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Laing G., Vigilato M.A.N., Cleaveland S., Thumbi S.M., Blumberg L., Salahuddin N.…Harrison W. One health for neglected tropical diseases. Trans. R. Soc. Trop. Med. Hyg. 2021;115(2):182–184. doi: 10.1093/trstmh/traa117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Okello A.L., Gibbs E.P.J., Vandersmissen A., Welburn S.C. One health and the neglected zoonoses: turning rhetoric into reality. Vet. Rec. 2011;169(11):281–285. doi: 10.1136/vr.d5378. [DOI] [PubMed] [Google Scholar]
  • 14.Kasozi K.I., Mujinya Regan, Bogere Paul, Ekou Justine, Zirintunda Gerald, Ahimbisibwe Salaviriuse.…Welburn Susan Christina. Pandemic panic and anxiety in developing countries. Embracing one health offers practical strategies in management of COVID-19 for Africa. Pan Afr. Med. J. 2020;35(2):3. doi: 10.11604/pamj.supp.2020.35.2.22637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Cleaveland S., Lankester F., Townsend S., Lembo T., Hampson K. Rabies control and elimination: a test case for one health. Vet. Rec. 2014;175(8):188–193. doi: 10.1136/vr.g4996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Nel L.H. Discrepancies in data reporting for rabies, Africa. Emerg. Infect. Dis. 2013;19(4):529–533. doi: 10.3201/eid1904.120185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Vigilato M.A.N., Clavijo A., Knobl T., Silva H.M.T., Cosivi O., Schneider M.C.…Espinal M.A. Progress towards eliminating canine rabies: policies and perspectives from Latin America and the Caribbean. Philos. Trans. R. Soc. B. 2013;368(1623):20120143. doi: 10.1098/rstb.2012.0143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Lefrançois T., Malvy D., Atlani-Duault L., Benamouzig D., Druais P.-L., Yazdanpanah Y.…Lina B. After 2 years of the COVID-19 pandemic, translating one health into action is urgent. Lancet. 2023;401(10378):789–794. doi: 10.1016/S0140-6736(22)01840-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Leifels M., Khalilur Rahman O., Sam I.-C., Cheng D., Chua F.J.D., Nainani D.…Chan Y.F. The one health perspective to improve environmental surveillance of zoonotic viruses: lessons from COVID-19 and outlook beyond. ISME Communicat. 2022;2(1):107. doi: 10.1038/s43705-022-00191-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Ruckert A., Zinszer K., Zarowsky C., Labonté R., Carabin H. What role for one health in the COVID-19 pandemic? Can. J. Public Health. 2020;111(5):641–644. doi: 10.17269/s41997-020-00409-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Tedros Adhanom WHO Director-General's Remarks at the Press Conference with President of the European COUNCIL to Discuss the Proposal for an International Pandemic Treaty. 2021. https://www.who.int/director-general/speeches/detail/who-director-general-s-remarks-at-the-member-state-briefing-on-the-report-of-the-international-team-studying-the-origins-of-sars-cov-2 Retrieved March 30, 2021, from.
  • 22.Banda G., Wangwe S., Mackintosh M. Making Medicines in Africa. Palgrave Macmillan UK; London: 2016. Making medicines in Africa: An historical political economy overview; pp. 7–24. [DOI] [Google Scholar]
  • 23.Ming A., Puddle J., Wilson H. Antimicrobial Resistance The Role of Regulation. 2019. https://www.ucl.ac.uk/global-governance/sites/global-governance/files/antimicriobial_resistance_the_role_of_regulation_final_draft_report_mb.pdf Retrieved January 24, 2024, from.
  • 24.O’Daniel M., Rosenstein A.H. An Evidence-Based Handbook for Nurses; Patient Safety and Quality: 2008. Professional Communication and Team Collaboration. [Google Scholar]
  • 25.Di Girolamo N., Meursinge Reynders R. Deficiencies of effectiveness of intervention studies in veterinary medicine: a cross-sectional survey of ten leading veterinary and medical journals. PeerJ. 2016;4 doi: 10.7717/peerj.1649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Butala C.B., Cave R.N.R., Fyfe J., Coleman P.G., Yang G.-J., Welburn S.C. Impact of COVID-19 on the neglected tropical diseases: a scoping review. Infect. Dis. Poverty. 2024;13(1):55. doi: 10.1186/s40249-024-01223-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Okello A.L., Welburn S.C. The importance of veterinary policy in preventing the emergence and re-emergence of zoonotic disease: examining the case of human African trypanosomiasis in Uganda. Front. Public Health. 2014;2:218. doi: 10.3389/fpubh.2014.00218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Franco J.R., Priotto G., Paone M., Cecchi G., Ebeja A.K., Simarro P.P.…Argaw D.D. The elimination of human African trypanosomiasis: monitoring progress towards the 2021–2030 WHO road map targets. PLoS Negl. Trop. Dis. 2024;18(4):1–22. doi: 10.1371/journal.pntd.0012111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Pfarr K.M., Krome A.K., Al-Obaidi I., Batchelor H., Vaillant M., Hoerauf A.…Kuesel A.C. The pipeline for drugs for control and elimination of neglected tropical diseases: 1. Anti-infective drugs for regulatory registration. Parasit. Vectors. 2023;16(1):82. doi: 10.1186/s13071-022-05581-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.FAO . Part 2: African Animal Trypanosomosis and Drug Resistance – A Challenge to Progressive, Sustainable Disease Control. FAO; Rome, Italy: 2022. Expert consultation on the sustainable management of parasites in livestock challenged by the global emergence of resistance; p. 48. Retrieved from. [DOI] [Google Scholar]
  • 31.Mulenga G.M., Henning L., Chilongo K., Mubamba C., Namangala B., Gummow B. 2019. Insights into the Control and Management of Human and Bovine African Trypanosomiasis in Zambia between 2009 and 2019 — A Review. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Selby R., Bardosh K., Picozzi K., Waiswa C., Welburn S.C. Cattle movements and trypanosomes: restocking efforts and the spread of Trypanosoma brucei rhodesiense sleeping sickness in post-conflict Uganda. Parasit. Vectors. 2013 doi: 10.1186/1756-3305-6-281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Anderson R.M., Cano J., Hollingsworth T.D., Deribe-Kassaye K., Zouré H.G.M., Kello A.B.…Vegvari C. Responding to the cuts in UK AID to neglected tropical diseases control programmes in Africa. Trans. R. Soc. Trop. Med. Hyg. 2023;117(3):237–239. doi: 10.1093/trstmh/trac109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Engels D., Zhou X.N. Neglected tropical diseases: an effective global response to local poverty-related disease priorities. Infect. Dis. Poverty. 2020 doi: 10.1186/s40249-020-0630-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.WHO Funding Crisis Threatens Africa's Fight Against Neglected Tropical Diseases. 2023. https://www.afro.who.int/news/funding-crisis-threatens-africas-fight-against-neglected-tropical-diseases Retrieved January 25, 2024, from.
  • 36.Ainsworth C. Tropical diseases move north. Nature. 2023 doi: 10.1038/d41586-023-03476-7. [DOI] [PubMed] [Google Scholar]
  • 37.Kennedy C.R.M., de Bruin Y.B., Lequarré A.-S., Ackerman R.T., Luster J., Tsang T.M.…Pilch R. One health security lessons from a year-long webinar series on international COVID-19 response. One Health Outlook. 2022;4(1):15. doi: 10.1186/s42522-022-00071-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Okello A., Vandersmissen A., Welburn S.C. In: One Health: The Theory and Practice of Integrated Health Approaches. Zinsstag J., Schelling E., Whittaker M., Tanner M., Waltner-Toews D., editors. CABI Publishing; Edinburgh: 2020. One health into action: Integrating global health governance with national priorities in a globalized world; pp. 283–303. [DOI] [Google Scholar]
  • 39.Mbonye A.K., Sekamatte M. Disease outbreaks and reporting in Uganda. Lancet. 2018 doi: 10.1016/S0140-6736(18)32414-0. [DOI] [PubMed] [Google Scholar]
  • 40.Waiswa C., Azuba R., Makeba J., Waiswa I.C., Wangoola R.M. Experiences of the one-health approach by the Uganda trypanosomiasis control council and its secretariat in the control of zoonotic sleeping sickness in Uganda. Parasit. Epidemiol. Control. 2020;11 doi: 10.1016/j.parepi.2020.e00185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Bakiika H., Obuku E.A., Bukirwa J., Nakiire L., Robert A., Nabatanzi M.…Lamorde M. Contribution of the one health approach to strengthening health security in Uganda: a case study. BMC Public Health. 2023;23(1):1498. doi: 10.1186/s12889-023-15670-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Global Initiative for Food Systems Leadership . University of Minnesota; 2011. Catalog of One Health Activities and Programs.http://www.foodssystemsleadership.org Retrieved from. [Google Scholar]
  • 43.University of Edinburgh Award for Sleeping Sickness Campaign. 2016. https://www.ed.ac.uk/unpublished/global-health/news-events/news-archive/2013-news/award-sleeping-sickness-campaig Retrieved January 25, 2024, from.
  • 44.Okello A.L., Bardosh K., Smith J., Welburn S.C. One health : past successes and future challenges in three African contexts. PLoS Negl. Trop. Dis. 2014;8(5):1–7. doi: 10.1371/journal.pntd.0002884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Maffioli E.M., Montás M.C., Anyakora C. Excessive active pharmaceutical ingredients in substandard and falsified drugs should also raise concerns in low-income countries. J. Glob. Health. 2024;14:03029. doi: 10.7189/jogh.14.03029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Buckley G.J., Gostin L.O. In: Countering the Problem of Falsified and Substandard Drugs. Gostin L.O., Buckley G.J., editors. National Academies Press; Washington, D.C.: 2013. Countering the problem of falsified and substandard drugs. [DOI] [PubMed] [Google Scholar]
  • 47.Tekle T., Terefe G., Cherenet T., Ashenafi H., Akoda K.G., Teko-Agbo A.…Delespaux V. Aberrant use and poor quality of trypanocides: a risk for drug resistance in south western Ethiopia. BMC Vet. Res. 2018;14(1):4. doi: 10.1186/s12917-017-1327-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Kasozi K.I., MacLeod E.T., Sones K.R., Welburn S.C. Trypanocide usage in the cattle belt of southwestern Uganda. Front. Microbiol. 2023;14(1):1296522. doi: 10.3389/fmicb.2023.1296522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.WHO OHHLEP Inventory of One HEALTH Tools and Resources. 2023. https://www.who.int/publications/m/item/ohhlep-inventory-of-one-health-tools Retrieved January 25, 2024, from.
  • 50.WHO Zero draft of the WHO CA+ for the Consideration of the Intergovernmental Negotiating Body at its Fourth Meeting. 2023. https://apps.who.int/gb/inb/pdf_files/inb4/A_INB4_3-en.pdf Retrieved from.
  • 51.Butchard P., Balogun B. What is the proposed WHO Pandemic Preparedness Treaty? 2023. https://researchbriefings.files.parliament.uk/documents/CBP-9550/CBP-9550.pdf Retrieved January 17, 2024, from.
  • 52.The White House National COVID-19 Preparedness Plan. 2022. https://www.whitehouse.gov/wp-content/uploads/2022/03/NAT-COVID-19-PREPAREDNESS-PLAN.pdf Retrieved January 25, 2024, from.
  • 53.Roozenbeek J., Schneider C.R., Dryhurst S., Kerr J., Freeman A.L.J., Recchia G.…van der Linden S. Susceptibility to misinformation about COVID-19 around the world. R. Soc. Open Sci. 2020;7(10) doi: 10.1098/rsos.201199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Sagan A., Webb E., McKee M., Greer S.L., Karanikolos M., Williams G.A.…Figueras J. European Observatory on Health Systems and Policies; Copenhagen, Denmark: 2021. Health Systems Resilience during COVID-19. Health Systems Resilience during COVID-19: Lessons for Building Back Better.https://www.ncbi.nlm.nih.gov/books/NBK590200/ Retrieved from. [PubMed] [Google Scholar]
  • 55.Terry K., Yang F., Yao Q., Liu C. The role of social media in public health crises caused by infectious disease: a scoping review. BMJ Glob. Health. 2023;8(12) doi: 10.1136/bmjgh-2023-013515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Wallace L.J., Agyepong I., Baral S., Barua D., Das M., Huque R.…Elsey H. The role of the private sector in the COVID-19 pandemic: experiences from four health systems. Front. Public Health. 2022;10 doi: 10.3389/fpubh.2022.878225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.GALVmed Funding for Tryps Phase 3 approved. 2018. https://www.galvmed.org/news/tryps-phase-3-funding-approved/ Retrieved November 1, 2021, from.
  • 58.GALVmed New partnership working on solutions to combat African animal trypanosomiasis. 2023. https://www.galvmed.org/news/new-partnership-working-on-solutions-to-combat-african-animal-trypanosomiasis/ Retrieved November 1, 2023, from.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

No data was used for the research described in the article.


Articles from One Health are provided here courtesy of Elsevier

RESOURCES